Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTyratech Regulatory News (TYR)

  • There is currently no data for TYR

Board Changes

7 Apr 2008 07:01

TyraTech, Inc.07 April 2008 For immediate release 7 April 2008 TYRATECH INC. ("TyraTech", "the Company" or "the Group") BOARD CHANGES TyraTech Inc. (AIM: TYR), a leading independent novel pesticide company forhuman, animal and environmental health, is pleased to announce that David PaulSzostak, aged 53, will join the Board of TyraTech as a Non-Executive Directorand that Rick Brenner, aged 54, Executive Director and founding CEO of TyraTechand VP of Business Development for XL TechGroup, will step down from the Board.Rick will continue his day to day business development responsibilities atTyraTech. Both of the Board changes outlined above will take place withimmediate effect. Mr. Szostak is an Executive Director, Chief Financial Officer and CompanySecretary at XL TechGroup, Inc. (AIM: XLT), and began his career in Chicago,Illinois working as a certified public accountant (CPA) for a large sizeaccountancy firm (Laventhol and Howarth) and later other smaller accountingfirms. He then moved into industry in 1987 as corporate controller at Extel,Inc., a global manufacturer of electronic communication equipment for industryand governments. When Extel acquired Hetra Computer, Inc., a manufacturer ofgovernment specialty computers, in 1990, Mr. Szostak relocated to Florida andaccepted the position of vice president and CFO of Hetra. In 1993, when XLVision, the predecessor company to XL TechGroup, acquired Hetra, Mr. Szostakcontinued in the same position with XL Vision. During his tenure at XL Vision,he was active in both the fundraising and public offerings of the XL Visionspin-out businesses. In addition to the accounting and finance functions, Mr.Szostak was responsible for many of the internal functions such as humanresources and benefits, legal, travel and facilities. Mr. Szostak earned hisBachelor of Science in Finance at Southern Illinois University, with graduatestudies at DePaul University in Chicago. XL TechGroup have a 47.92% stake in TyraTech. Mr. Szostak's previous and current Directorships include the following:Company Name Date of DirectorshipeMerge Interactive, Inc. 1996 - 97Sanctuary HO Association 2002 - 04ANX LLC (formerly AgCert International LLC) 2002 - 03XL TechGroup LLC 2001 - 04XL TechGroup, Inc 2004- PresentXL TechGroup Employee 2007- PresentCharitable Fund, IncDxTech LLC 2005 - PresentPetroAlgae LLC 2006 - PresentGenXL LLC 2006 - Present There are no further details required to be disclosed pursuant to Schedule Two,paragraph (g) of the AIM Rules. Commenting on this announcement, Geoffrey N. Vernon, Non-Executive Chairman ofTyraTech, said: "I would like to thank Rick Brenner for his considerablecontribution to TyraTech as an Executive Board member and am delighted that hewill continue his day to day responsibilities assisting TyraTech. We welcomeDavid to the Board and look forward to working with him." For further information please contact:TyraTech Inc. +1 (321) 409 7403Douglas Armstrong Ph.D., Chief Executive Officerwww.tyratech.com Nomura Code Securities +44 (0)20 7776 1200Charles Walker/Clare Terlouwwww.nomuracode.com Buchanan Communications +44 (0) 20 7466 5000Mary-Jane Johnson mary-jane.johnson@buchanan.uk.comLisa Baderoon/Catherine Breenwww.buchanan.uk.com About TyraTech TyraTech was formed in 2004 to develop and commercialise products for thecontrol of invertebrate pests and pathogens using the Company's proprietarytechnology. TyraTech, which already has products on the market, is positionedfor human health, animal health and pesticide market opportunities which totalover $23 billion globally. TyraTech's technology provides the Company with awide variety of product and business opportunities in many markets andgeographic regions. The differentiating feature of these products is thepotential to have a combined level of potency and safety that other invertebratecontrol products are unable to offer. TyraTech's platform brings many of theprinciples of drug discovery and development to the fields of insecticides andparasiticides. By targeting specific chemoreceptors that are found ininvertebrates but not in humans and animals, TyraTech can produce products thatuse natural plant derived compounds targeting these receptors. TyraTech's plan for the use of its technology is to develop selected proprietaryactive ingredients which can then be used across a wide variety of marketsegments, either by development partners or by TyraTech itself. TyraTech alreadyhas products or partnerships in the areas of professional and horticulturalinsect control, and for an insect/mosquito repellent. TyraTech also has aninnovative partnership with Kraft to use its natural oils to develop functionalfoods for helping control of parasitic infections and diseases that affect morethan 2 billion people worldwide. TyraTech also has a separate technology with associated intellectual propertythat is the basis for the Sustainable Solutions business. This technology hasbeen incorporated into specialised dairy farm equipment for processing cattlemanure waste to a usable material for TyraTech to sell as a commercial plantgrowing medium. For more information please visit www.tyratech.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
14th Jan 20147:00 amRNSChange of Adviser
14th Jan 20147:00 amRNSVamousse coming to Walmart stores in the USA
18th Dec 20137:00 amRNSBlocklisting Interim Review
25th Oct 20132:39 pmRNSDirector/PDMR Shareholding
7th Oct 20138:39 amRNSDirector/PDMR Shareholding
30th Sep 20137:00 amRNSInterim Results
14th Aug 20137:00 amRNSGlobal distribution agreement for biocide products
25th Jul 20136:11 pmRNSResult of AGM
27th Jun 20137:00 amRNSFinal Results
24th Jun 20137:00 amRNSDirectorate Changes
19th Jun 20139:59 amRNSBlocklisting Interim Review
11th Jun 20134:23 pmRNSDirectorate Change
31st May 201312:43 pmRNSMigration of Shares
11th Apr 20137:00 amRNSFrench Registration of Insect Repellent Product
9th Apr 20137:00 amRNSHolding(s) in Company
28th Mar 20136:09 pmRNSResult of Special Meeting
28th Mar 20134:15 pmRNSShare Migration
19th Mar 20137:00 amRNSAppointment of Financial PR and IR advisor
18th Mar 20137:00 amRNSProposed placing and subscription of common shares
4th Mar 20137:00 amRNSUK registration of insect repellent product
4th Feb 20137:00 amRNSFirst Patent Granted for ExtendT Technology
30th Jan 20137:00 amRNSAMVAC and TyraTech Name New Joint Venture
10th Jan 20137:00 amRNSDirectorate Change
7th Jan 201310:40 amRNSNew Anti-Endoparasitic Composition Patents
20th Dec 20127:00 amRNSIssue of Equity
18th Dec 20122:56 pmRNSBlocklisting Interim Review
18th Dec 20127:00 amRNSGerman Registration of Insect Repellent Product
17th Dec 20127:00 amRNSFirst Shipment of Retail Products
11th Dec 20127:00 amRNSHead Lice Product Registration in UK
4th Dec 20127:00 amRNSFormation of New Joint Venture
13th Nov 20127:00 amRNSU.S. Registration of New Insect Repellent Product
7th Nov 20122:10 pmRNSProactive Investors One2One Investor Forum
30th Oct 20127:00 amRNSAdvance Payment on Prospective New Alliance
29th Oct 20127:00 amRNSChange of Name of Adviser
16th Oct 201211:40 amRNSTyraTech Secures New Patent
16th Oct 20129:26 amRNSMigration of Shares
1st Oct 20127:00 amRNSInterim Results
28th Sep 20121:15 pmRNSInterim Results
26th Sep 20127:00 amRNSProducts to Launch at The Home Depot
25th Sep 20127:00 amRNSTrademark Licensing Agreement with Terminix
10th Aug 20123:02 pmRNSMigration of Shares
25th Jul 20123:55 pmRNSResult of AGM
6th Jul 20124:36 pmRNSMigration of Shares
2nd Jul 20121:18 pmRNSDirector/PDMR Shareholding
2nd Jul 201211:39 amRNSDirector/PDMR Shareholding
28th Jun 20127:00 amRNSFinal Results
18th Jun 20127:00 amRNSBlocklisting Interim Review
22nd May 20127:00 amRNSTrading Update
14th May 20127:00 amRNSIssue of Equity
10th May 20127:00 amRNSMigration of Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.